Filling the need for trusted information on national health issues…

Tuberculosis

  • Your Selections:

Refine Results

date

Tags

WHO Says Global TB Cases Decline For First Time Ever But Warns Funding Gap, Resistant Strains Put Progress At Risk

New data published in the WHO’s 2011 Global Tuberculosis Control Report on Tuesday, “shows that the number of people who fell ill with [tuberculosis (TB)] dropped to 8.8 million in 2010, after peaking at 9 million in 2005,” the U.N. News Centre reports. “The report shows that the TB death rate dropped 40 percent between 1990 and 2010, and all regions, except Africa, are on track to achieve a 50 percent decline in mortality by 2015,” the news service writes (10/11). “The countries the WHO especially noted for progress in the fight against the disease were Kenya, [Tanzania], Brazil and China,” Reuters reports (Selyukh/Ulmer-Nebehay, 10/11).

Study Finds Vitamin D Is Critical In Human Immune Response To Tuberculosis

“Vitamin D is needed to activate the immune system’s response to tuberculosis (TB),” a finding that “could lead to new treatments for the lung disease,” researchers from the University of California in Los Angeles (UCLA) said in a study published Wednesday in the journal Science Translational Medicine, Agence France-Presse reports. “Researchers have long known that vitamin D plays a role in the body’s response to TB, but the study … shows it must be present in adequate levels to trigger the immune response,” AFP writes.

Russia Pledges Money To Support HIV, TB Programs In Neighboring Countries

“Russia plans to step up its international role in fighting infectious disease across eastern Europe and central Asia, in what some observers see as the latest effort by the Kremlin to reassert its political influence over its former Soviet neighbors,” the Financial Times reports. “Arkady Dvorkovich, economic aide to President Dmitry Medvedev, pledged money for a new international development agency to support programs against HIV and tuberculosis (TB)” at the Millennium Development Goal 6 Forum hosted in Moscow last week, the newspaper notes.

Treating TB, HIV Co-Infections Early, Aggressively Can Save Lives, Multiple Studies Show

“Treating tuberculosis (TB) and HIV infections at the same time can be a challenge for patients and their doctors, but attacking both diseases early and aggressively isn’t harmful and could save the lives of those who are sickest,” according to a global study led by researchers from the University of California, San Francisco (UCSF) and published Wednesday in the New England Journal of Medicine (NEJM), the San Francisco Chronicle reports. The study found that patients whose immune systems have been most damaged by HIV were 40 percent less likely to die or develop AIDS if they began antiretroviral treatment (ART) “two weeks after starting TB treatment, instead of waiting eight to 12 weeks, as is commonly done now,” the newspaper writes.

E-Voucher Program Providing Food To Malnourished Zimbabweans Living With HIV, TB

An electronic voucher system, introduced by the World Food Programme (WFP) and implemented by the health ministry and non-governmental organizations, is helping Zimbabweans living with HIV/AIDS and tuberculosis (TB) and their families obtain food and fight malnutrition, PlusNews reports. “The program supports about 5,000 patients and their families with essential food items and is operating at seven health facilities in the capital [Harare] and has been extended to the second-largest city, Bulawayo,” the news service writes.

Committed Action, Continued Funding Needed In Global Campaign Against TB

A Lancet editorial responds to the WHO’s sixteenth annual report on global tuberculosis (TB) control, released on Oct 11, which shows that the incidence of tuberculosis has been falling worldwide since 2002, writing, “Successes in disease control in China and other countries show what sustained political and economic support can achieve. Rather than waiting for the elixir of economic success to arrive in all high-burden countries, committed action by donors, agencies, and governments in the most challenging settings is needed in the global campaign against tuberculosis.”

Eli Lilly To Pledge $30M To MDR-TB Partnership

Pharmaceutical firm Eli Lilly and Co. is expected to announce on Tuesday it “is pledging $30 million to help fight multidrug-resistant tuberculosis [MDR-TB] in developing countries, a disease that kills more than 150,000 people a year,” according to the Indianapolis Star. The funds, part of the company’s eight-year-old, $165 million Lilly MDR-TB Partnership, will help to “provide training for nurses, doctors and community volunteers; conduct studies on how to combat the disease; and provide access to medicines,” the newspaper notes. The campaign will focus on China, India, Russia and South Africa, “the four countries with the highest burden of MDR-TB, Lilly said,” the Indianapolis Star writes (10/25).

Wall Street Journal Looks At European Efforts To Fight TB

The Wall Street Journal examines efforts to fight tuberculosis (TB) in Europe, writing, “All along the edges of Western Europe, new and hard-to-defeat strains of tuberculosis are gaining a foothold, often moving beyond traditional victims — alcoholics, drug users, HIV patients — and into the wider population.” The article focuses on the efforts of Estonia to turn the tide against multidrug-resistant TB, saying the country’s success “offers one of the few bright spots globally as the ancient plague mutates into new and more deadly forms.” The newspaper continues, “Indeed, experts say the country, with half the population of Chicago, could be a model for others. But there is one catch: It takes years and some pricey treatments just to gain the upper hand” (Naik, 12/31).

Reflecting On FDA Approval Of New TB Drug

Noting “[t]he U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant [tuberculosis (TB)] that can be used as an alternative when other drugs fail,” Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition’s “Breakthroughs” blog, “There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant.” She continues, “It is also noteworthy that the FDA approved Sirturo under its accelerated approval program, in addition to granting the drug fast track, priority review, and orphan-product status,” adding, “It’s critical that the FDA continues to support its priority review, fast track, and similar programs, which can help speed access to safe and effective global health drugs” (1/3).

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/KaiserFamFound

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.